Concepedia

Author

Kathleen Cox

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

Cox, Kathleen A., 1965-, K Cox, K. A. Cox, K. Cox, K.A Cox, K.A. Cox, Kathleen A Cox, Kathleen A. COX, Kathleen A. Cox, Kathleen Cox

78

Publications

3.9K

Citations

34

H-Index

85

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Purdue University West LafayetteEli Lilly (United States)
KC

About

Kathleen Cox is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

24

28

2.4K

2

Natural Sciences

15

15

1.2K

3

Engineering

4

4

197

4

Social Sciences

2

2

505

5

Health Sciences

1

1

11

Kathleen Cox

×

42

Publications

3.6K

Citations

32

H-Index

YearCitations

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen,

Science Translational Medicine

2016

407

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection<i>in vitro</i>and<i>in vivo</i>

Julie Strizki, Serena Xu, Nicole Wagner,

Proceedings of the National Academy of Sciences

2001

300

Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1

Julie Strizki, Cécile Tremblay, Serena Xu,

Antimicrobial Agents and Chemotherapy

2005

214

Role of the site of protonation in the low-energy decompositions of gas-phase peptide ions

Kathleen Cox, Simon J. Gaskell, Michael Morris,

Journal of the American Society for Mass Spectrometry

1996

177

Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease

Jack D. Scott, Sarah W. Li, Andrew P. J. Brunskill,

Journal of Medicinal Chemistry

2016

161

Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor

Jared N. Cumming, Elizabeth M. Smith, Lingyan Wang,

Bioorganic & Medicinal Chemistry Letters

2012

151

Cassette‐accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery

Walter A. Korfmacher, Kathleen Cox, Kwokei Ng,

Rapid Communications in Mass Spectrometry

2001

151

Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. IV. Discovery of 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-{2-methoxy-1(<i>R</i>)-4-(trifluoromethyl)phenyl}ethyl-3(<i>S</i>)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a Potent, Highly Selective, and Orally Bioavailable CCR5 Antagonist

Jayaram R. Tagat, Stuart W. McCombie, Dennis V. Nazareno,

Journal of Medicinal Chemistry

2004

136

Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. II. Discovery of 1-[(2,4-Dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(<i>S</i>)-methyl-4-[1(<i>S</i>)-[4-(trifluoro- methyl)phenyl]ethyl]-1-piperazinyl]- piperidine <i>N</i>1-Oxide (Sch-350634), an Orally Bioavailable, Potent CCR5 Antagonist

Jayaram R. Tagat, Ruo W. Steensma, Stuart W. McCombie,

Journal of Medicinal Chemistry

2001

112

Chemiluminescence Detection of Amino Acids, Peptides, and Proteins Using Tris-2,2′-Bipyridine Ruthenium (III)

Li He, Kathleen Cox, Neil D. Danielson

Analytical Letters

1990

111

Page 1